Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative, with each initiative independently offering the potential to drive significant liquidity and materially strengthen the Company's balance sheet.
UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.12 and traded as low as $0.1740. ProPhase Labs shares last traded at $0.1998, with a volume of 490,748 shares traded. Analyst Upgrades and Downgrades Several equities
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.26 and traded as low as $0.1661. ProPhase Labs shares last traded at $0.2799, with a volume of 1,509,825 shares changing hands. Analyst Ratings Changes Several research
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base.
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Risk and Volatility ProPhase Labs has a beta
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.
Grifols (NASDAQ: GRFS - Get Free Report) and ProPhase Labs (NASDAQ: PRPH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation. Institutional and Insider Ownership 9.4% of ProPhase Labs shares
ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript
UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab's Chairman and CEO Ted Karkus.
